Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency

Basit Öğe Kaydı
dc.authoridCelik, Emir/0000-0001-8440-3082
dc.contributor.authorCelik, Emir
dc.contributor.authorSamanci, Nilay Sengul
dc.contributor.authorKaradag, Mehmet
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorCikman, Duygu Ilke
dc.contributor.authorDerin, Sumeyra
dc.contributor.authorBedir, Sahin
dc.date.accessioned2024-09-18T20:52:47Z
dc.date.available2024-09-18T20:52:47Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIntroduction Erlotinib is an effective treatment option for EGFR-mutant non-small cell lung cancer. It is important to predict patients who will respond better to erlotinib. We designed this study to investigate the effect of renal insufficiency (RI) on erlotinib treatment outcomes. Methods All patients receiving erlotinib were stratified into 3 groups. Group 1 consisted of non-RI subjects with classical epidermal growth factor receptor (EGFR) mutations, Group 2 consisted of those with RI (Estimated glomerular filtration rate <60 mL/min) and classical EGFR mutations, and Group 3 consisted of those with non-classical EGFR mutations. Results 82 patients were included in the study. Median progression-free survival (PFS) in patients with classical mutation was approximately 6 months shorter in those with RI, although not statistically significant. Median overall survival (OS) in Group 1, 2 and 3 was 34.1 months, 35.2 months, and 15 months, respectively and although not statistically significant, median OS was 20 months shorter in Group 3. Univariate and multivariate cox-regression analysis revealed shorter PFS and OS in males and those with ECOG >= 2 while PFS and OS were longer in those with recurrent lung tumors and generating rash during erlotinib treatment. There was no difference between RI and non-RI patients in terms of adverse events except for fatigue and appetite loss. Conclusions This research showed OS in patients with and without RI was comparable. Although not statistically significant, PFS in patients with classical mutation was approximately 6 months shorter in those with RI patients.en_US
dc.identifier.doi10.1177/1078155220964895
dc.identifier.endpage1673en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue7en_US
dc.identifier.pmid33040673en_US
dc.identifier.scopus2-s2.0-85092508370en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1665en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220964895
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11394
dc.identifier.volume27en_US
dc.identifier.wosWOS:000578553100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectlung canceren_US
dc.subjecterlotiniben_US
dc.subjectrenal insufficiencyen_US
dc.titleClassical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiencyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
615.37 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu